Combined treatment with metformin and gefitinib overcomes primary resistance to EGFR-TKIs with EGFR mutation via targeting IGF-1R signaling pathway

AIM: Although EGFR tyrosine kinase inhibitors (TKIs) have shown dramatic effects against sensitizing EGFR mutations in non-small cell lung cancer (NSCLC), ~20%–30% of NSCLC patients with EGFR-sensitive mutation exhibit intrinsic resistance to EGFR-TKIs. The purpose of the current study was to invest...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Biologics
Main Authors: Pan, Yong-hong, Jiao, Lin, Lin, Cai-yu, Lu, Cong-hua, Li, Li, Chen, Heng-yi, Wang, Yu-bo, He, Yong
Formato: Artigo
Idioma:Inglês
Publicado em: Dove Medical Press 2018
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6108345/
https://ncbi.nlm.nih.gov/pubmed/30154647
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BTT.S166867
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados